Trade
Pharma braces for a tariff shock: industry warns US drug duties would hit patients and supply chains
The next big pharma risk isn’t a trial readout — it’s trade policy. Switzerland’s pharma industry body Interpharma warned that proposed US tariffs on pharmaceuticals would disrupt supply chains and ultimately raise prices for patients. The politics are loud, but the operational detail matters: drug manufacturing and packaging is deeply cross-border, and sudden duties can force costly re-routing of API and finished-dose flows. The implication for 2026: expect companies to accelerate “where is this made?” disclosures, regionalize critical steps, and hedge with more redundant manufacturing — all of which shows up in COGS.
Source: Reuters